Institutional Exposure To Adaptimmune Therapeutics Plc ADR (ADAP)
Adaptimmune Therapeutics Plc ADR (ADAP) concluded trading on Thursday at a closing price of $0.57, with 4.65 million shares of worth about $2.65 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -42.12% during that period and on December 26, 2024 the price saw […]
Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) Seen Running Too Hot, Let’s Look At This More Closely
Currently, there are 255.70M common shares owned by the public and among those 226.47M shares have been available to trade. The company’s stock has a 5-day price change of -10.81% and -42.32% over the past three months. ADAP shares are trading -21.45% year to date (YTD), with the 12-month market performance up to 14.31% higher. […]
Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP): To Buy Or Not To Buy, That Is The Question
Adaptimmune Therapeutics Plc ADR (ADAP) concluded trading on Thursday at a closing price of $0.73, with 3.31 million shares of worth about $2.42 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -28.22% during that period and on November 28, 2024 the price saw […]
Is Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) Back In The Buying Zone?
Currently, there are 227.17M common shares owned by the public and among those 226.31M shares have been available to trade. The company’s stock has a 5-day price change of -14.98% and -43.29% over the past three months. ADAP shares are trading -14.91% year to date (YTD), with the 12-month market performance up to 40.88% higher. […]
Assessing Whether Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) Is Over- Or Undervalued
Adaptimmune Therapeutics Plc ADR (ADAP) concluded trading on Thursday at a closing price of $0.59, with 14.5 million shares of worth about $8.56 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -50.73% during that period and on November 14, 2024 the price saw […]
Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) – Suitable For Long Term Buy?
Insiders at the company have transacted a total of 0 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 0 of these insider trades were purchases, accounting for 0 shares. Insider sales of the common stock occurred on 0 occasions, with total insider shares sold totaling […]
